Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
URSODIOL TABLETS | IMPURITIES/Organic Impurities/Procedure | USP36–NF31 | 5520 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Sample solution: Change Tablets, equivalent to about 25 mg of ursodiol, to: Tablets, equivalent to about 250 mg of ursodiol, |
SORBITAN MONOPALMITATE | IDENTIFICATION/A. | USP36–NF31 | 2213 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 210–225 to: 210–225 on 1-g sample |
BETHANECHOL CHLORIDE | IMPURITIES/Heavy Metals, Method 1 <231> | Second Supplement to USP36–NF31 | 6568 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Test preparation: Change Bethacholine Chloride to: Bethanechol Chloride |
POWDERED STINGING NETTLE | COMPOSITION/Content of Total Amino Acids | USP36–NF31 | 1606 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Reagent solution: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin, |
MEPROBAMATE TABLETS | ASSAY/Procedure | First Supplement to USP36–NF31 | 6015 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 4 of Standard solution: Change Dissolve in 30% of the final flask volume, and dilute with water to volume. to: Dissolve in 30% of the final flask volume of acetonitrile, and dilute with water to volume. |
BETAMETHASONE SODIUM PHOSPHATE | Identification/B. Thin-Layer Chromatographic Identification Test <201> | USP36–NF31 | 2645 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Test solution: Change 1 mg per mL. to: 1 mg per mL in methanol. |
DACARBAZINE FOR INJECTION | USP Reference standards <11> | USP36–NF31 | 3137 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of USP Dacarbazine Related Compound B RS: Change C4H3N5O 137.10 to: C4H3N5O · H2O 155.12 |
EDETATE DISODIUM | ASSAY/Procedure | USP36–NF31 | 3370 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 5: Delete Titrimetric system (See Titrimetry <541>.) Mode: Direct titration Titrant: 0.1 N sodium hydroxide VS Endpoint detection: Visual |
LAMOTRIGINE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 1 | USP36–NF31 | 4056 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 3 of Standard solution: Change 0.028 µg/mL to: 0.028 mg/mL |
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities/Table 2 | USP36–NF31 | 5438 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote c: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual… Read More |
PURIFIED GYMNEMA EXTRACT | COMPOSITION/Content of Gymnemic Acids | First Supplement to USP36–NF31 | 5884 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Acceptance criteria: Change 90%–110% of the labeled amount to: 90.0%–110.0% of the labeled amount on the dried basis |
SODIUM HYDROXIDE | ASSAY/Procedure | USP36–NF31 | 2203 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 11 of Analysis: Change = volume of Titrant consumed by the Sample to the first endpoint (mL) to: = volume of Titrant consumed by the Sample to the second endpoint (mL) |
CLARITHROMYCIN FOR ORAL SUSPENSION | ASSAY/Procedure | USP36–NF31 | 3018 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Change the subsection head Buffer: to: Buffer A: AND After the Buffer A subsection: Add Buffer B: 0.067 M dibasic potassium phosphate AND Line 1 of Mobile phase: Change Methanol and Buffer to: Methanol and Buffer A… Read More |
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION | Assay | USP36–NF31 | 3276 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride. to: Mobile phase—Prepare a solution of acetonitrile, water,… Read More |
FEXOFENADINE HYDROCHLORIDE TABLETS | ASSAY/Procedure | USP36–NF31 | 3576 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 6 of Sample stock solution: Change (equivalent to 80% of the total flask volume) to: (sufficient to fill the flask to 80% of its volume) |
NIFEDIPINE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 4/Instrumental conditions | USP36–NF31 | 4509 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Cell: Change 0.5 cm to: 1 cm |
GYMNEMA | IDENTIFICATION/B. Thin-Layer Chromatography/Chromatographic system | First Supplement to USP36–NF31 | 5880 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Adsorbent: Change 5m to: 5 µm |
POWDERED STINGING NETTLE EXTRACT | COMPOSITION/Content of Total Amino Acids | USP36–NF31 | 1608 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Reagent solution: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin, |
OXCARBAZEPINE | IMPURITIES/Organic Impurities, Procedure 1 | First Supplement to USP36–NF31 | 6035 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Row 4 of Column 1 of Table 1: Change Dibenzazepinoneb to: Oxcarbazepine related compound E AND Delete footnote b AND Reletter the following footnotes in both the table and footnote definitions: c to b d to c e to d |
CALCIUM CARBONATE | IMPURITIES | USP36–NF31 | 2747 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Acceptance criteria in Limit of Fluoride: Change 50 ppm to: NMT 50 ppm AND Line 1 of Acceptance criteria in Mercury, Method IIa <261>: Change 0.5 ppm to: NMT 0.5 ppm |
CRYOPRESERVED HUMAN FIBROBLAST-DERIVED DERMAL SUBSTITUTE | Total collagen content | USP36–NF31 | 3155 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 7 of Collagen calibration standards: Change by adding 25 mL, 50 mL, 100 mL, and 200 mL, to: by adding 25 μL, 50 μL, 100 μL, and 200 μL, |
EDETATE DISODIUM | ASSAY/Procedure | USP36–NF31 | 3370 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 16 of Analysis: Change Calculate the percentage of edetate disodium to: Calculate the weight of edetate disodium AND Line 19 of Analysis: Change Result = (VT/VU) × W × (Mr1/Mr2) ×… Read More |
LEVOFLOXACIN | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 4099 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of USP Levofloxacin Related Compound A RS: Change (S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4-benzoxazine-6-carbocylic acid. to: (S)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-… Read More |
VENLAFAXINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 5551 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2… Read More |
STINGING NETTLE | COMPOSITION/Content of Total Amino Acids | USP36–NF31 | 1604 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Reagent solution: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin, |
GENTAMICIN SULFATE | IMPURITIES/Limit of Methanol | First Supplement to USP36–NF31 | 5990 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 11 of Analysis:
Change Result = (RU/RS) × (CS/CU) × D × F × 100 to: Result = (RU/RS) × (CS… Read More |
AMOXICILLIN | IMPURITIES/Organic Impurities/Procedure | USP36–NF31 | 2477 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Acceptance criteria: Change [Note—The reporting limit is 0.03% of the amoxicillin peak from the Standard solution. ] to: [Note—The reporting limit is 0.03 times the amoxicillin peak from the Standard solution. ] |
CLARITHROMYCIN EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 4 | USP36–NF31 | 3019 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Standard solution: Change and Medium (96:4). to: and Medium (4:96). |
DIPHENHYDRAMINE HYDROCHLORIDE ORAL SOLUTION | Assay | USP36–NF31 | 3277 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride. to: Mobile phase—Prepare a solution of acetonitrile, water,… Read More |
FLUPHENAZINE DECANOATE INJECTION | Assay | USP36–NF31 | 3639 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 11 of Standard preparation: Delete (1:5) AND Line 8 of Assay preparation: Delete (1:5) |
OLMESARTAN MEDOXOMIL | IMPURITIES/Organic Impurities/Impurity Table | USP36–NF31 | 4570 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote d: Change ((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(2-trityl-1… Read More |
POWDERED GYMNEMA | IDENTIFICATION/B. Thin-Layer Chromatography/Chromatographic system | First Supplement to USP36–NF31 | 5883 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Adsorbent: Change 5m to: 5 µm |
GLYCERYL DISTEARATE | ASSAY/Procedure/Chromatographic system | USP36–NF31 | 2029 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Column temperature: Change Column temperature: 40° to: Temperatures Detector: 40° Column: 40° |
OXCARBAZEPINE | IMPURITIES/Organic Impurities, Procedure 2 | First Supplement to USP36–NF31 | 6035 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Row 9 of Column 1 of Table 3: Change Oxcarbazepine related compound Eg to: Oxcarbazepine related compound E AND Delete footnote g |
CEFDINIR CAPSULES | IMPURITIES/Organic Impurities/Table 2 | USP36–NF31 | 2850 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Row 16 of Column 1: Change Cefdinir impurity 2e to: Cefdinir impurity 2f AND Row 21 of Column 1: Change Cefdinir impurity 3e to: Cefdinir impurity 3f |
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES | Assay | USP36–NF31 | 3276 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, System suitability solution, and Chromatographic system—Prepare as directed in the Assay under Diphenhydramine Hydrochloride. to: Mobile phase—Prepare a solution of acetonitrile, water,… Read More |
FELBAMATE TABLETS | IMPURITIES/Organic Impurities/System suitability/Suitability requirements | USP36–NF31 | 3537 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Resolution: Change NMT 2 to: NLT 2 |
MOXIFLOXACIN OPHTHALMIC SOLUTION | Related compounds | USP36–NF31 | 4414 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Row 1 of Column 3 of Table 2: Change Relative Retention Time vs. Moxifloxacin to: Relative Retention vs. Moxifloxacin AND Row 1 of Column 3 of Table 3: Change Relative Retention Time vs. Moxifloxacin to: Relative Retention vs. Moxifloxacin |
VENLAFAXINE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 5554 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2… Read More |
ALBUTEROL SULFATE | Chromatographic purity | USP36–NF31 | 2352 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1: Change It meets the requirements of the test for Chromatographic purity under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Test solution. to… Read More |
MINOCYCLINE HYDROCHLORIDE CAPSULES | Assay | USP36–NF31 | 4375 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate… Read More |
NIFEDIPINE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | USP36–NF31 | 4509 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Solution A: Change Dissolve 330.9 mg of sodium phosphate to: Dissolve 330.9 g of dibasic sodium phosphate |
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE FOR EFFERVESCENT ORAL SOLUTION | Assay for potassium | USP36–NF31 | 4834 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Potassium stock solution and Standard preparations— to: Standard stock solution and Standard solutions— AND Line 1 of Procedure: Change for Procedure in the Assay under Potassium Chloride Oral Solution. to… Read More |
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS | Dissolution <711> | USP36–NF31 | 4841 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 5: Change Potassium stock solution— to: Standard stock solution— AND Line 7: Change Prepare as directed for Standard preparations to: Prepare as directed for Standard solutions AND Line 7 of Procedure: Change for … Read More |
THIMEROSAL TOPICAL AEROSOL | SPECIFIC TESTS/Alcohol Determination, Method II <611> | USP36–NF31 | 5369 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 4 of Analysis: Change Determine the alcohol content of the sample thus prepared by the Gas–Liquid Chromatographic Method (see Method II in Alcohol Determination <611>, using methyl ethyl ketone as the internal standard in place of acetone. to: … Read More |
CARAWAY OIL | DEFINITION | USP36–NF31 | 1924 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3: Change It contains NMT 50.0% of d-carvone (C10H14O). to: It contains NLT 50.0% of d-carvone (C10H14O). |
NORTRIPTYLINE HYDROCHLORIDE | IMPURITIES/Organic Impurities | First Supplement to USP36–NF31 | 6027 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Acceptance criteria: Change Standard solution to: Sample solution |
FOSPHENYTOIN SODIUM INJECTION | USP Reference standards <11> | USP36–NF31 | 3680 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 6: Change C14H15NO2 to: C14H13NO2 |
MINOCYCLINE HYDROCHLORIDE TABLETS | Assay | USP36–NF31 | 4378 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2: Change Mobile phase, Standard preparation, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Minocycline Hydrochloride. to: Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M… Read More |
PENTAZOCINE INJECTION | Chemical Information | USP36–NF31 | 4734 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1: Remove all chemical information. |